Bangi Inc (BNGI)

[goarmy123]

Penny stock profit is the first one.

Here is the promo.


PSP Free Members,

We've got a low-cost, low-float Biotech stock that has caughtmy attention due to increased activity, as well as a few key technicalindicators showing a bullish outlook in the near term.

The stock is trading at only $0.02 per share currently, and hasa history of rewarding traders with past gains of well over 100% in just dayswhen momentum took hold.

In fact... last month this stock had a 200% single-day-gain!

The recent trading volume over the last 2 days is what's capturedmy interest:

Over the last 2 trading sessions, this stocks volume has been more thanDOUBLE the 10-day moving average, and I believe this tiny biotech stock may besetting the stage for another one of its breakout trading sessions!

Make sure you review the entire alert tonight, especiallythe 'technical indicators' section near the bottom of this email.

It's not very often that we alert these low-cost, low-floatpicks, but when we do, they can often times provide crazy gains formembers. I would not besurprised if this stock had another breakout day tomorrow should momentum continueto build.

Begin your research starting with this alert rightaway. This stock looks capable ofseeing some big movement fast. From a technical perspective COBI needs just a sliver of momentum tokick start it on a potentially huge run that could climb up the charts at anymoment!

-James

+++++++++++++++++++++++++++++++++++++++++++++++++++++++

NEW PICK

Compass Biotech Inc


COBI

COBI Chart



Currently Trading: $0.022

COBI Real Time 'Bid & Ask' Prices

HERE IS THE SECOND PROMO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!



COBI - $0.02 Cent Biotech Stock - Momentum Alert!

SecretStockPromoter [e-mail] via aweber.com



6:31 PM (3 hours ago)

Images are not displayed. Display images below - Always display images from [e-mail]

Secret Stock Trial Members,
You are receiving notice of my current stock promotion! If you like the resultsand would like to start receiving my alerts before the crowd you can sign up for a 1 time fee of $97 at:

www.SecretStockPromoter.com/info.php

Sincerely,
Jeff Thompson


My promotedStock for Thursday, January 12th!

COBI

CompassBiotechnologies Inc. (OTC: COBI.PK)

Last Price:$0.02


COBIAnnounces New Strategy and Expanded Focus to Include New Women's HealthFranchise and Hepatitis Treatment!


CompassBiotech Inc. Announces Significant Pact with PanGen Biotech and a Relationshipwith Arecor Ltd. !


A report issued by well-known researchanalyst Grass Roots Research Distribution concludes COBI is on track to meettargets and expects valuation and share price to rise!



Secret Stock Trial Members,


While the Biotech sector offers plenty ofpotentially lucrative investment opportunities overall, Compass Biotechnologies Inc. or COBI, looks especially promising forinvestors looking for a low entry and potentially big gains within a short holdperiod.

At just $0.02 per share, COBIhas a very low float giving this stock play the potential for singleday double-digit gains! Add tothat a strong forward company outlook based on an aggressive new strategy and asolid management team to execute, COBI could be a huge winner for investorsthat can move faster than the potential speed at which this stock could shootup the charts!

COBI has a 52 week high of about $0.02 per share, making its current entry ofaround $0.02 extremely low while carrying a low float which gives it the potential to move upwards significantlywithout institutional support and within a very short time frame.

Compass Biotechnology Inc. has formed anew operational structure with subsidiaries focusing on building value in 4 key targeted areas, diversified toallow for immediate revenue generation as well as development of proprietaryproducts to support growth in the long term. With HepatitisC treatments as a major area of focus, COBI has the potential to emerge as aleader in a multi-billion dollar market,and with its new foray into Women's Health to generate revenues in theimmediate term, Compass looks to be developing a very promising future. COBI is poised to pick up velocity andgiven its technical characteristics, even a small amount of momentum could bejust the catalyst to jump start this stock on a massive run up the charts verysoon!

I highly suggest you begin your researchimmediately on COBI: a company primed to see big gains!


About Compass Biotechnologies Inc.

Compass Biotechnologies Inc.,a development stage biotechnology company, engages in the development oflicenses for patents pertaining to the technology utilized in the preventionand treatment of hepatitis C. It focuses on the development andcommercialization of generic, biosimiliar, and biobetter drugs.

Corporate Website: http://www.compassbio.net



CBOI Breaking News:

In a December 22,2011 press release, Compass Biotechnologies Inc. announced a new strategy andexpanded focus in Women's Health, and in addition will seek to build value inseveral other key areas. In order to facilitate this new strategy Compass announceda new structure whereby it has formed 4 operational divisions that will bedirected by Compass management and specialized management teams with expertiseto develop and commercialize the various product groupings.

Dr.Joseph Sinkule, President of Compass Biotechnologies Inc. states, "the four subsidiaries will be managed on a day to daybasis by a team of talented development people with past experience in each ofthe four franchise areas," going on to say, "The value growth and revenue-generation created by each of thesubsidiaries will be funneled to Compass and Compass shareholders." (Read More)

According to a December 23,2011 "QualityStock's" article in SeekingAlpha.com, the subsidiaries will focuson the following 4 key areas:

1. Diagnostics, Reagents andSupplements (Compass Scientific)

Compass Scientific willprovide near-term revenue through sales and distribution of products toresearchers and to manufacturers requiring bulk GMP-cytokins and growth factorssuch as recombinant human insulin.

2. Hepatitis Franchise (C-Pharma Inc.)

C-Pharma Inc. will capitalizeon the low risk and rapid approval of generic drugs used to treat hepatitis C,with the long-term upside potential of the company's preventative vaccinesagainst these diseases, tapping into a market with multibillion dollarpotential

3. "BioBetters" orRecombinant Protein Therapeutics(Compass Biotech)

Compass Biotech will utilizecollaborative efforts to improve biosimilar proteins such as EPO and G-CSF toproduce improved formulations and better products.

4. Women's Health Franchise(GenBio Inc.)

GenBio Inc. will focus oncommercialization of products based on unique medical and diagnostic needs forwomen around the world. (Read More)

Inaddition, The activities of the subsidiarieswill be funded through the efforts of Compass and a registered offering plannedfor early 2012. Compass has engaged advisors to raiseapproximately $5 million as abridge financing in Q1 2012 leading to a larger secondary offering later in2012.

CEO of Compass, Garth Likes states,"the advisory group has completeddue diligence of Compass and its 4-point value creation business model and stated that they believe each operatingunit on their own has great financial potential in product development,with some of these units being able togenerate near-term revenue while others offering breakthrough products thatwill take longer to develop."

(Read More)

Biotech MarketPotential:

The Hepatitis CTherapy market is enormous, estimatedto be valued in the billions of dollars, which has prompted manypharmaceutical and biotechnology companies to focus enormous efforts and significant sums of money todevelop treatments.

According todiagnostic company Innogenetics, which develops diagnostic assays in InfectiousDiseases, studies have shown 1 in 30people globally are chronically infected, with Hepatitis C now 4 to 5 times more widespread than HIVand reports of 3-4 million newinfections per year. Thestudy also shows that the market fortreatment will grow from a current $3 Billion to over $10 Billion by the year2015. (Read More)

A World HealthOrganization Statistic cited in 2011 Reutersreport indicated 350,000 deaths annually from HCV related liverdiseases and showed that about staggering 130-170 Million people worldwide are chronically infected with HCV. (Read More)

The Hepatitis CVaccine market potential for CompassBiotechnologies Inc. is approximately $2 Billion according to CompassCEO, Garth Likes. But withCompass' recent announcement that newresearch findings that lead Compass to believe it will alter the course of HCVvaccine development and other vaccines in general, CEO Garth Likessays, "with the development of a second anti-HCV type product based on newscientific findings that augments to make an HVC vaccine even more potent, thenthis means sales could jump to muchhigher levels, making Compass [Biotechnoloies Inc.] the market leaders in thisarea."


CBOI TechnicalIndicators:

A strong short termupward trend seems to be developing for with the ADX values increasing above 20and as evidenced by the DI+ line's position above the DI- line when examiningthe 7 Day Average Directional Indicator, supporting a bullish outlook for COBIin the near term. The 50 DayParabolic Time vs. Price chart shows the indicator below the price linetypically signaling a "BUY" action.

With an extremelylow float and COBI trading far below its 52 week high, this $0.02 per sharestock has the potential to jump high and fast on the back of even nominalmomentum gains, and could easily see 70% plus gains in as little as a day! With COBI's new strategy to captureimmediate revenues while allowing for a strong focus in the Hepatitis Ctreatment market for long-term growth, COBI looks very undervalued at itscurrent price. At $0.02 per share, COBI offers a veryattractive short term opportunity for double digit gains while carrying thepotential to emerge as the market leader in a multibillion dollar sector!

From atechnical perspective COBI looks very promising, giving investors astock play opportunity with a low entry, high potential, and a very shortinterest period. There could bemajor success ahead for Compass Biotechnology Inc. prompting investors to paycloser attention and kickstarting some serious momentum soon. With its current qualities thatrequires very little momentum for a rapid climb up the charts, COBI could be onthe verge of a breakout run any minute! Watch COBI closely throughout this week, we could see some veryimpressive movement.

I recommendresearching COBI this evening and keeping on eye on this one throughout theweek. This could be the perfectstock play for big returns fast!

Yours truly,

Jeff Thompson

www.SecretStockPromoter.com/info.php

Disclaimer: (Please Read Entire Disclaimer)

Never invest in anystock featured in the SecretStockPromoter.com email alerts unless youcanafford to lose your entire investment. Many of the stocks featured arehighly volatileand speculative in nature. SecretStockPromoter.com has been compensated Thirty Five Thousand Dollars by a third party, EurolinkInvesments Incfor a one day advertisingcampaign regarding Compass Biotechnologies Inc (COBI.PK). The thirdparty may have shares and may sell them at any time. Neither JeffThompson or any of the SecretStockPromoter.comemployees are registered as investment advisors, financial analysts,brokers,or dealers in any jurisdiction whatsoever. Your use of theSecretStockPromoter.comemail alerts, means that you agree to hold SecretStockPromoter.com, itsoperators, owners, and employees harmless and to completely release them fromany and all liability due to any and all loss (monetary or otherwise),damage(monetary or otherwise), or injury (monetary or otherwise) that you maysuffer.Neither the information presented nor any statement or expression ofopinion,or any other matter herein, directly or indirectly constitutes asolicitationfor the purchase or sale of any securities. The information provided isobtained from sources deemed reliable, but SecretStockPromoter.com doesnotguarantee in any way the timeliness, sequence, accuracy, adequacy, orcompleteness of such information made regarding stocks discussed inSecretStockPromoter.comemail alerts.

The owner, publisher,editor and their associates are not responsible for errors andomissions. Youunderstand and agree that at the time of any transaction you make,SecretStockPromoter.comemployees, SecretStockPromoter.com affiliates, and friends and family of JeffThompson and SecretStockPromoter.com owners and operators may have apositionin such securities. The position may have been acquired prior to thepublication of any website information or email alert. You should alsobe awarethat the aforementioned parties do have the right to sell theirpositions atany time without further notification. Any opinions expressed aresubject to changewithout notice SecretStockPromoter.com encourages readers and investorsto supplementthe information in these reports with independent research and otherprofessional advice. All information on featured companies is providedby thecompanies profiled, or persons affiliated with or associated with suchcompanies; or is available from public sources. Read our full disclaimer at: http://secretstockpromoter.com/page.php?page=disclaimer



123 Main St
Huntington beach CA 92646